Last $35.86 USD
Change Today -0.09 / -0.25%
Volume 848.3K
AUXL On Other Exchanges
As of 4:30 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

640 Lee Road

Chesterbrook, PA 19087

United States

Phone: 484-321-5900

Fax: 484-321-5999

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing and commercializing products for specialist audiences. The company has strategically expanded its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. With the April 26, 2013 acquisition of Actient Holdings, LLC (Actient), the company markets 12 products (including 1 product with 2 indications) in the urology, orthopedic, respiratory and other areas in the U.S. and internationally through its respective collaborators. Among other products in the U.S., Auxilium markets Testim (testosterone gel) for the topical treatment of hypogonadism, TESTOPEL (testosterone pellets) a long-acting implantable testosterone replacement therapy (TRT) product, STENDRA (avanafil), an oral erectile dysfunction (ED) therapy, Edex (alprostadil for injection), an injectable treatment for ED, Osbon ErecAid, the vacuum device for aiding ED, XIAFLEX (collagenase clostridium histolyticum) for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture. The company also has programs in Phase 2 clinical development for the treatment of Frozen Shoulder syndrome and cellulite. Marketed Products Testim 1% (testosterone gel) is a topical TRT for the treatment of hypogonadism. Ferring International Center S.A. markets Testim in certain countries of the European Union (EU) and Paladin Labs Inc. (Paladin) (which is in the process of being acquired by Endo Health Solutions Inc. (Endo) markets Testim in Canada. TESTOPEL is a long-acting implantable TRT product. STENDRA is an oral therapy for ED, for which the company also has Canadian marketing rights, launched in the U.S. in 2014. Edex is the branded non-oral drug for ED. Osbon ErecAid is the vacuum device for treating ED. Striant is a buccal TRT. XIAFLEX is used for the treatment of adult Dupuytren's contracture patients with a palpable cord. Swedish Orphan Biovitrium AB (Sobi) has marketing rights for XIAPEX (the EU) tradename for collagenase clostridium histolyticum) in 71 Eurasian and African countries; Asahi Kasei Pharma Corporation (Asahi Kasei) has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd (Actelion) has development and commercial rights for XIAFLEX in Canada, Australia, and Brazil. XIAFLEX is used for the treatment of Peyronie's disease in men with a palpable plaque and a curvature deformity of thirty degrees or greater at the start of therapy, which was launched in the U.S. in January 2014 and is the U.S. Food and Drug Administration (FDA) approved non-surgical treatment for Peyronie's disease. The company’s respiratory products include Theo-24 for the treatment of COPD and asthma; and Semprex-D for the treatment of seasonal allergic rhinitis. The company’s promoted products are sold through three focused sales forces, totaling approximately 326 field personnel. These sales forces are organized as follows: Team PRIMERA consists of approximately 150 territories and is responsible for Testim, STENDRA and Edex; Team INNOVIA consists of approximately 60 territories and is responsible for selling TESTOPEL, XIAFLEX for Peyronie's disease and Osbon ErecAid; and Team AGILIS consists of 47 territories and is responsible for selling XIAFLEX for Dupuytren's contracture. Development Pipeline The company submitted in 2013 a supplemental Biologics License Application to the FDA approval of XIAFLEX for the treatment of multiple Dupuytren's contracture cords concurrently. Its strategic partner, VIVUS, Inc. (VIVUS) submitted in 2013 a request for a label expansion for an approximately 15-minute onset of action efficacy claim for STENDRA. The company’s product XIAFLEX is used for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite, with a Phase 2a trial having commenced in 2013. Its XIAFLEX is used for the treatment of Adhesive Capsulitis, commonly known as Frozen Shoulder syndrome, with a Phase 2b trial having commenced in 2013. Testosterone In 2013, the company conducted initial clinical studies for a potential high co

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AUXL:US $35.86 USD -0.09

AUXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acrux Ltd A$1.50 AUD +0.085
Actavis plc $285.02 USD +5.90
Antares Pharma Inc $2.34 USD -0.01
Endo International PLC $79.15 USD +0.28
Mylan Inc/PA $56.80 USD +2.59
View Industry Companies

Industry Analysis


Industry Average

Valuation AUXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 11.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUXILIUM PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at